PER-023-18已完成未知
A 2-TREATMENT PERIOD, RANDOMIZED, PLACEBO-CONTROLLED,MULTICENTER PARALLEL-GROUP STUDY TO ASSESS THE SAFETY OFQAW039 WHEN ADDED TO EXISTING ASTHMA THERAPY IN GINASTEPS 3, 4 AND 5 PATIENTS WITH UNCONTROLLED ASTHMA
OVARTIS BIOSCIENSES PERU S.A.,0 个研究点目标入组 69 人开始时间: 2018年11月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 69
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Informed Consent Form and assent if applicable.
- •2. Completion of the Treatment Period (on blinded study drug) of a prior Phase 3 study of QAW039.
- •3. Patient is able to safely continue into the study as judged by the investigator.
排除标准
- •1. Patients who did not complete the Treatment Period on blinded study drug of the prior phase 3 study of QAW039 they participated in.
- •2. Inability to comply with all study requirements.
- •3. Patients who experienced a serious and drug-related AE in the prior phase 3 study of QAW039 they participated in
研究者
相似试验
已完成
不适用
The study will be conducted to monitor the safety of subjects participating in the study and to assess the bioequivalence between (A) Doxorubicin Hydrochloride 2 mg/mL (50 mg/m2 dose) and (B) (Doxorubicin Hydrochloride) 2 mg/ml (50 mg/m2 dose) in cancer patients.CTRI/2016/12/007611Sun Pharmaceutical Industries Limited48
已完成
3 期
Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma TreatmentAsthmaJPRN-jRCT2080223509ovartis Pharma K.K.200
已完成
3 期
Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma TreatmentRespiratory - AsthmaRespiratory , AsthmaJ45.9LBCTR2019121309ovartis Pharma Services Inc.20
进行中（未招募）
1 期
Study of safety of QAW039 in patients (= 12 yrs) with asthma inadequately controlled on standard-of-care asthma therapyMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2016-001560-11-ATovartis Pharma AG2,406
进行中（未招募）
1 期
Study of safety of QAW039 in patients (= 12 yrs) with asthma inadequately controlled on standard-of-care asthma therapyAsthmaEUCTR2016-001560-11-PLovartis Pharma AG2,406